rts logo

Biocryst Pharmaceuticals Inc. (BCRX) Stock Could Soon Reward Patient Investors

Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX) is -15.69% lower on its value in year-to-date trading and has touched a low of $4.82 and a high of $9.06 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BCRX stock was last observed hovering at around $5.08 in the last trading session, with the day’s loss setting it -0.03%.

Currently trading at $5.05, the stock is -3.26% and -7.03% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.87 million and changing -0.59% at the moment leaves the stock -19.58% off its SMA200. BCRX registered -41.00% loss for a year compared to 6-month loss of -30.25%. The firm has a 50-day simple moving average (SMA 50) of $4.46 and a 200-day simple moving average (SMA200) of -$12.72.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The stock witnessed a -10.30% gain in the last 1 month and extending the period to 3 months gives it a -17.08%, and is 0.80% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.45% over the week and 5.49% over the month.

Biocryst Pharmaceuticals Inc. (BCRX) has around 536 employees, a market worth around $1.04B and $331.41M in sales. Profit margin for the company is -68.36%. Distance from 52-week low is 4.88% and -44.29% from its 52-week high. The company has generated returns on investments over the last 12 months (-61.73%).

Biocryst Pharmaceuticals Inc. quarterly earnings per share for the current quarter are estimated at -$0.21 with sales reaching $86.29M over the same period.The EPS is expected to grow by 46.44% this year, but quarterly earnings will post 19.40% year-over-year. Quarterly sales are estimated to grow 25.50% in year-over-year returns.

Biocryst Pharmaceuticals Inc. (BCRX) Top Institutional Holders

321 institutions hold shares in Biocryst Pharmaceuticals Inc. (BCRX), with institutional investors hold 89.14% of the company’s shares. The shares outstanding are 205.77M, and float is at 198.55M with Short Float at 15.38%. Institutions hold 88.05% of the Float.

The top institutional shareholder in the company is Blackrock Inc. with over 15.5 million shares valued at $109.09 million. The investor’s holdings represent 8.18% of the BCRX Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 15.09 million shares valued at $106.23 million to account for 7.96% of the shares outstanding. The other top investors are Baker Brothers Advisors, LLC which holds 12.71 million shares representing 6.71% and valued at over $89.48 million, while State Street Corporation holds 6.47% of the shares totaling 12.26 million with a market value of $86.34 million.

Biocryst Pharmaceuticals Inc. (BCRX) Insider Activity

The most recent transaction is an insider sale by SANDERS MACHELLE,the company’sDirector. SEC filings show that SANDERS MACHELLE sold 4,000 shares of the company’s common stock on Jun 15 ’23 at a price of $7.98 per share for a total of $31920.0. Following the sale, the insider now owns 25611.0 shares.

Biocryst Pharmaceuticals Inc. disclosed in a document filed with the SEC on Jun 14 ’23 that Hutson Nancy J (Director) sold a total of 12,866 shares of the company’s common stock. The trade occurred on Jun 14 ’23 and was made at $8.04 per share for $0.1 million. Following the transaction, the insider now directly holds 81818.0 shares of the BCRX stock.

Still, SEC filings show that on Apr 03 ’23, Thackray Helen M. (Chief R&D Officer) disposed off 7,000 shares at an average price of $8.29 for $58030.0. The insider now directly holds 207,275 shares of Biocryst Pharmaceuticals Inc. (BCRX).

Related Posts